Amplia Therapeutics Limited (ASX:ATX)
Australia
· Delayed Price · Currency is AUD 0.157
-0.008 (-4.85%)
Apr 29, 2026, 3:23 PM AEST
Amplia Therapeutics Revenue
Amplia Therapeutics had revenue of 2.63M AUD in the half year ending September 30, 2025, with 7.44% growth. This brings the company's revenue in the last twelve months to 5.01M, up 46.79% year-over-year. In the fiscal year ending March 31, 2025, Amplia Therapeutics had annual revenue of 3.78M, down -15.03%.
Revenue (ttm)
5.01M
Revenue Growth
+46.79%
P/S Ratio
16.91
Revenue / Employee
n/a
Employees
n/a
Market Cap
84.66M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 3.78M | -669.04K | -15.03% |
| Mar 31, 2024 | 4.45M | 3.26M | 274.34% |
| Mar 31, 2023 | 1.19M | -793.83K | -40.03% |
| Mar 31, 2022 | 1.98M | 449.80K | 29.33% |
| Mar 31, 2021 | 1.53M | 1.50M | 4,380.44% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Cynata Therapeutics | 1.69M |
| Botanix Pharmaceuticals | 21.92M |
| Arovella Therapeutics | 3.21M |
| Radiopharm Theranostics | 16.28M |
| LTR Pharma | 1.13M |
| Paradigm Biopharmaceuticals | 8.45K |
| Immutep | 7.92M |
| Island Pharmaceuticals | 62.85K |
Amplia Therapeutics News
- 6 days ago - Accent Trial Mature Data Presented at International Conference - GlobeNewsWire
- 6 weeks ago - Amplia Therapeutics to Present at the Life Sciences Investor Forum on March 12th - GlobeNewsWire
- 7 weeks ago - Poster Presentation Demonstrating Combination Benefit of Narmafotinib in Preclinical Kras-Mutated Cancer Models - GlobeNewsWire
- 2 months ago - Amplia Therapeutics Announces Opening of US Sites for Amplicity Pancreatic Cancer Trial - GlobeNewsWire
- 3 months ago - Amplia Therapeutics - Quarterly Activities and Cash Flow Reports - December 2025 - GlobeNewsWire
- 3 months ago - ACCENT DATA PRESENTED AT 2026 ASCO GASTROINTESTINAL CANCER SYMPOSIUM - GlobeNewsWire
- 4 months ago - Amplia Therapeutics to Present at 2026 ASCO Gastrointestinal Cancers Symposium - GlobeNewsWire
- 4 months ago - Additional Confirmed Response Reported as Part of Amplia Investor Presentation - GlobeNewsWire